The ABHD6 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ABHD6 gene in the human 143B osteosarcoma cell line. This loss-of-function model disrupts ABHD6 expression, providing a tool for studying endocannabinoid metabolism and its cellular consequences. The polyclonal pool comprises a heterogeneous mixture of edited cells, reflecting a population-wide gene inactivation without the constraints of clonal selection.
The 143B cell line originates from a human osteosarcoma and is characterized by its aggressive tumorigenic properties. As a model of cancerous bone-forming cells, 143B cells are widely utilized for investigating osteosarcoma biology, including proliferation, migration, and metabolic regulation. Their robust growth and well-documented signaling networks make them an ideal host for gene-editing approaches aimed at dissecting pathways relevant to bone cancer progression.
ABHD6 is a monoacylglycerol lipase that hydrolyzes 2-arachidonoylglycerol (2-AG), a key endocannabinoid. By regulating 2-AG levels, ABHD6 controls activation of the CB1 receptor and subsequent signaling through MAPK/ERK and PI3K/AKT cascades. In the endocannabinoid system, ABHD6 functions alongside MAGL and FAAH in 2-AG degradation, while DAGL?? drives its synthesis. This enzymatic network balances 2-AG tone, influencing cell proliferation, migration, and lipid metabolism. The precise upstream regulation of ABHD6 remains under investigation, though it may be influenced by lipid-sensing transcription factors. Membrane lipid interactions likely play a role in its localization and activity.
Within osteosarcoma cells, ABHD6 knockout is predicted to raise 2-AG concentrations, thereby augmenting CB1-mediated signaling and downstream ERK/AKT activation. Alternatively, accumulated 2-AG may be shunted toward eicosanoid production, altering inflammatory and proliferative cues. Such changes can impact tumor cell migration, invasiveness, and metabolic reprogramming, making this knockout model valuable for probing the intersection of endocannabinoid signaling and cancer cell biology.
Applications include the study of endocannabinoid-dependent modulation of osteosarcoma behavior, cancer metabolism, and drug target validation. Researchers can confirm ABHD6 disruption via Western blot or RT-qPCR, quantify 2-AG by LC-MS, assess signaling changes with phospho-ERK measurements, and conduct functional assays such as MTT, Transwell migration, and colony formation. The polyclonal knockout format supports robust, population-level phenotypic analysis. For further information, contact Ascent Research.
